Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?
Executive Summary
Bristol's surprising purchase diversifies its portfolio beyond Opdivo, while stopping Celgene's ongoing stock price declines after several setbacks. While Bristol execs downplayed the mid-term risk of generics for Celgene's blockbuster Revlimid, they highlighted near- and long-term growth drivers.
You may also be interested in...
BMS Broadens Market, De-Risks Long-Term Revenue Potential For Reblozyl
As a first-line treatment for anemia in patients with myelodysplastic syndromes, Reblozyl is approved for indications that will account for 75%-80% of the $4bn-plus in sales Bristol has forecast by 2029.
Bristol’s Boerner To Succeed CEO Caforio With Launch Execution In The Spotlight
Giovanni Caforio will step down as CEO of Bristol Myer Squibb effective 1 November, with chief commercialization officer Boerner primed to succeed him.
BMS’s Phase III Reblozyl Trial Hits Mark In First-Line, Lower-Risk Myelodysplastic Syndrome
The drug’s success in the Phase III COMMANDS trial could double its addressable market, though some analysts said durability remains a question.